Angiosarcoma of the LiverSymptoms, Doctors, Treatments, Advances & More
Angiosarcoma of the Liver Overview
Learn About Angiosarcoma of the Liver
View Main Condition: Angiosarcoma
- Angiosarcoma of the liver
University Of Louisville Physicians - Gastroenterology
Matthew Cave is a Gastroenterologist practicing medicine in Louisville, Kentucky. Dr. Cave is rated as an Elite provider by MediFind in the treatment of Angiosarcoma of the Liver. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Angiosarcoma of the Liver, Alcoholic Cirrhosis, Endoscopy, and Gastrectomy. Dr. Cave is board certified in American Board Of Internal Medicine, Gastroenterology - 2007 and American Board Of Internal Medicine, Transplant Hepatology - 2010 . Dr. Cave is currently accepting new patients.
David Semela practices practicing medicine in Sankt Gallen, Switzerland. Mr. Semela is rated as an Elite expert by MediFind in the treatment of Angiosarcoma of the Liver. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Angiosarcoma of the Liver, Hepatitis C, Angiosarcoma, Hepatitis, and Liver Transplant.
Rockefeller Outpatient Pavilion
Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Advanced provider by MediFind in the treatment of Angiosarcoma of the Liver. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.
Summary: AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progressio...
Summary: The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational stud...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center
